2nd LEAD CANDIDATE

Camidanlumab Tesirine (Cami)

Cami is ADCT’s second lead candidate. It has demonstrated significant clinical activity in heavily pretreated patients with Hodgkin lymphoma. Based on its mechanism targeting CD25/regulatory T cells, Cami is also demonstrating potential in the treatment of solid tumors.

Cami targets CD25/regulatory T cells

Cami is an ADC composed of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to a PBD dimer toxin. Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based warhead. In addition to CD25-expressing tumor cells, Cami depletes CD25-positive Tregs in the local tumor environment, which enhances immune-mediated anti-tumor activity.

Cami is being evaluated in several clinical trials

Studies include a pivotal phase 2 clinical trial in patients with relapsed or refractory (R/R) Hodgkin lymphoma (NCT04052997); a phase 1a/1b clinical trial in patients with R/R Hodgkin lymphoma and non-Hodgkin lymphoma (NCT02432235); and a phase 1b clinical trial in solid tumors (NCT03621982).

The clinical development of this product is ongoing. Camidanlumab Tesirine (ADCT-301) is an investigational agent. The safety and efficacy has not yet been established.

VIEW OUR RESEARCH